[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"secondary-hemophagocytic-lymphohistiocytosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:secondary-hemophagocytic-lymphohistiocytosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100659214","phase-3-efficacy-of-short-course-of-intravenous-dexamethasone-and-intravenous-immunoglobulin-therapy-in-infection-related-secondary-hemophagocytic-lymphohistiocytosis-ishlh-100659214",false,"NCT07861776","Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)","Randomized Controlled Trial to Evaluate and Compare the Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (sHLH)","isHLH-IVD\u002FIVIg","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Gender: Male\u002Ffemale\n* h-Score probability ≥ 80%\n* Known microbiological etiology\n* Mild HLH not responding to infection specific targeted antimicrobial therapy (\\> 72 hours)\n* Mild HLH developing new organ dysfunction\n* Moderate to severe HLH with life threatening organ dysfunction\n\nExclusion Criteria:\n\n* Primary (familial) HLH\n* Malignancy associated HLH\n* HLH associated with autoimmune disease\n* EBV associated HLH\n* Pregnancy\n* Receiving immune modulator therapy within 2 moths\n* Participants with HIV\n* Consent not given\n* Known hypersensitivity to IVIG or Dexamethasone\n* Chronic liver disease\n* Chronic kidney disease","ALL","18 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Rationale\u002FGaps in Existing Knowledge: Therapy of Infection-associated Secondary Hemophagocytic lymphohistiocytosis (sHLH) in adult lacks evidence from randomized trial guiding first-line immunomodulation and current therapeutic practice primarily extrapolated from decades old pediatric HLH protocols and retrospective studies. In presence of infection very expensive therapy with intravenous Immunoglobulin (IVIG) is preferred over Dexamethasone, however the comparative efficacy of IVIG and Dexamethasone alone remains undefined, especially in resource-constraints settings. (ii) Novelty: This will be among the first randomized controlled trials in adults with infection-associated sHLH, directly comparing efficacy of IVIG with Dexamethasone. The study uniquely integrates clinical outcomes with economic feasibility in a low-middle income setting. (iii) Objectives: Primary objectives will be to compare the efficacy of intravenous (IV) Dexamethasone and IVIG in achieving clinical remission and recovery of HLH-associated cytokines (IL-1, IL-6, TNF-α, IFN-γ, GM-CSF) and Ferritin level. Secondary objectives include assessment of hematologic recovery, adverse events, and short-term mortality. (iv)Method: In this Randomized controlled open-label, non-inferiority clinical trial participants with sHLH, will be allocated (1:1) to receive either short-course of IV Dexamethasone or IVIG along with infection-directed standard care and will be followed-up for 4 weeks to evaluate predefined clinical outcome and laboratory parameters. (v) Expected Outcome: The study aims to establish whether IV Dexamethasone is non-inferior to IVIG for achieving clinical remission, recovery of HLH-associated cytokines level and reduction of short-term mortality. Results are expected to reform evidence-based, cost-effective therapeutic strategies for infection-associated sHLH and improve access to care in resource-constraint healthcare systems.",[27,28],"Hemophagocytic Lymphohistiocytosis (HLH)","Secondary Hemophagocytic Lymphohistiocytosis",[30,31,32,33],"Hemophagocytic lymphohistiocytosis (HLH)","Dexamethasone","Intravenous Immunoglobulin (IVIg)","Infection associated secondary HLH (isHLH)","NOT_YET_RECRUITING","2026-10-01",{"date":37,"type":38},"2026-10-06","ACTUAL",{"date":40,"type":21},"2026-10-15",{"date":42,"type":21},"2029-09-30",{"name":44,"class":45},"Post Graduate Institute of Medical Education and Research, Chandigarh","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100542154","hemophagocytic-lymphohistiocytosis-hlh-evaluation-and-research-of-clinical-immunologic-and-transcriptome-study-100542154","NCT06339177","Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study","* INCLUSION CRITERIA:\n* Aged 18 years or older.\n* Established diagnosis of sHLH defined by meeting any published criteria, per Table 1:\n\n  * Meeting the HLH-2004 criteria.\n  * HScore of \\>168. For those without a bone marrow biopsy to evaluate for hemophagocytosis (worth 35 points in the criteria), HScore\\>134 will be used.\n  * For those with underlying rheumatologic disease: meeting the 2016 American College of Rheumatology criteria for macrophage activation syndrome.\n* Agree to storage and sharing of study data and biospecimens for future research use.\n\nTable 1: Published Criteria for HLH\n\nHLH-2004 Criteria:\n\nMolecular diagnosis of HLH OR At least 5 of 8 below criteria:\n\n* Fever (\\>38.4 Degrees Celcius)\n* Splenomegaly\n* Cytopenias affecting \\>=2 of 3 lineages: Hgb \\\u003C9 g\u002FdL, platelets \\\u003C10\\^5\u002Fmicroliter, neutrophils \\\u003C10\\^6\u002Fmicroliter\n* Hypertriglyceridemia (\\>256 mg\u002FdL) and\u002For fibrinogen \\\u003C1.5 g\u002FL\n* Hemophagocytosis on biopsy\n* Serum ferritin \\>=500 ng\u002FmL\n* Increased serum sCD25 (\\>2400 U\u002FmL)\n* Low or absent NK cell activity\n\nHScore:\n\nKnown immunosuppression:\n\n0 (no) or 18 (yes)\n\nTemperature (degrees, Celsius):\n\n0 (\\\u003C38.4), 33 (38.4-39.4), 49 (\\>39.4)\n\nOrganomegaly:\n\n0 (no), 23 (liver\u002Fspleen), 38 (both)\n\nNumber of cytopenias:\n\n0 (1 lines), 24 (2 lines), 34 (3 lines)\n\nFerritin (ng\u002FmL):\n\n0 (\\\u003C2000), 35 (2000-6000), 50 (\\>6000)\n\nTriglycerides (mg\u002FdL):\n\n0 (\\\u003C1.5), 44 (1.5-4), 66 (\\>4)\n\nFibrinogen (g\u002FL):\n\n0 (\\>2.5), 30 (\\\u003C2.5)\n\nAST (IU\u002FmL):\n\n0 (\\\u003C30), 19 (\\>30)\n\nHemophagocytosis:\n\n0 (no) or 35 (yes)\n\nCutoff value=169\n\nACR 2016-MAS Criteria:\n\nA febrile patient with known or suspected sJIA is classified as having macrophage activation syndrome if the following criteria are met:\n\nFerritin \\>684 ng\u002FmL\n\nAND any 2 of the following:\n\n* Platelets \\\u003C=181,000\u002Fmicroliter\n* AST \\>48 IU\u002FmL\n* Triglycerides \\>156 mg\u002FdL\n* Fibrinogen \\\u003C=3.6 g\u002FL\n\nAbbreviations: ACR, American College of Rheumatology; AST, aspartate transaminase; Hgb, hemoglobin; HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; NK, natural killer, sJIA, systemic juvenile idiopathic arthritis.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Currently pregnant.\n* Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","120 Years",{"count":54,"type":21},300,"OBSERVATIONAL","Background:\n\nHemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH.\n\nObjective:\n\nTo learn about sHLH and why some people get it and others do not.\n\nEligibility:\n\nAdults aged 18 years and older with sHLH.\n\nDesign:\n\nParticipants will be admitted to the study based on a review of their medical records. Those who join will have at least 3 clinical evaluations over 9 to 12 months. These may occur during an inpatient hospitalization if they require medical care or in the outpatient clinic.\n\nParticipants will also have a physical exam at each visit. Up to half a cup of blood will be drawn at each visit. Participants may also have their blood drawn by their own doctors, who will send the samples to the researchers. Researchers may also contact these participants by telephone or video calls.\n\nThe blood will be used for clinical tests as well as research. No new treatments will be administered as part of this study; however, standard medications and treatments may be recommended.\n\nParticipants may opt to continue their visits once a year for 3 more years. Participants may also opt for an extra clinial evaluation 1 week after starting a new treatment.\n\n...",[58,28,59,60],"Lymphohistiocytosis, Hemophagocytic","Macrophage Activation Syndrome","Hyperinflammatory Syndromes",[62,63,59,64,65,66,67,68,69,70],"Hemophagocytic Lymphohistiocytosis","HLH","MAS","Cytokine Storm Syndrome","Hyperinflammatory Syndrome","Hyperinflammation","Still's Disease","Hyperferritinemia","Immune Dysregulation","RECRUITING","2026-09-09",{"date":74,"type":38},"2026-09-10",{"date":76,"type":38},"2024-07-02",{"date":78,"type":21},"2031-04-01",{"name":80,"class":81},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH"]